BioRestorative Therapies, Inc. (BRTX)
NASDAQ: BRTX · Real-Time Price · USD
0.2510
-0.0270 (-9.71%)
At close: Apr 6, 2026, 4:00 PM EDT
0.2565
+0.0055 (2.19%)
Pre-market: Apr 7, 2026, 8:50 AM EDT
BioRestorative Therapies Revenue
In the year 2025, BioRestorative Therapies had annual revenue of $359.70K, down -10.30%. BioRestorative Therapies had revenue of $19.60K in the quarter ending December 31, 2025, a decrease of -54.73%.
Revenue (ttm)
$359.70K
Revenue Growth
-10.30%
P/S Ratio
17.78
Revenue / Employee
$25,693
Employees
14
Market Cap
6.40M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 359.70K | -41.30K | -10.30% |
| Dec 31, 2024 | 401.00K | 255.20K | 175.03% |
| Dec 31, 2023 | 145.80K | 26.00K | 21.70% |
| Dec 31, 2022 | 119.80K | 73.80K | 160.43% |
| Dec 31, 2021 | 46.00K | -31.00K | -40.26% |
| Dec 31, 2020 | 77.00K | -53.00K | -40.77% |
| Dec 31, 2019 | 130.00K | 19.00K | 17.12% |
| Dec 31, 2018 | 111.00K | 30.00K | 37.04% |
| Dec 31, 2017 | 81.00K | 44.65K | 122.80% |
| Dec 31, 2016 | 36.36K | -592.56K | -94.22% |
| Dec 31, 2015 | 628.92K | 212.92K | 51.18% |
| Dec 31, 2014 | 416.00K | 414.32K | 24,661.67% |
| Dec 31, 2013 | 1.68K | -13.91K | -89.22% |
| Dec 31, 2012 | 15.59K | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xenetic Biosciences | 2.98M |
| CollPlant Biotechnologies | 2.37M |
| Can-Fite BioPharma | 405.00K |
| Kiora Pharmaceuticals | 20.00K |
| Creative Medical Technology Holdings | 6.00K |
| Alaunos Therapeutics | 5.00K |
BRTX News
- 8 days ago - BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease - GlobeNewsWire
- 19 days ago - BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease - GlobeNewsWire
- 4 weeks ago - BioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026 - GlobeNewsWire
- 5 weeks ago - BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs - GlobeNewsWire
- 7 weeks ago - BioRestorative Announces Closing of $5.0 Million Public Offering - GlobeNewsWire
- 7 weeks ago - BioRestorative Announces Pricing of $5.0 Million Public Offering - GlobeNewsWire
- 7 weeks ago - BioRestorative Announces Positive Outcome from Type B Meeting with FDA - GlobeNewsWire
- 5 months ago - BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025 - GlobeNewsWire